

ZILBRYSQ REMS**What you need to know about ZILBRYSQ****What is ZILBRYSQ?**

ZILBRYSQ (zilucoplan) is a prescription medicine that is used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is injected under the skin.

What are the serious risks of ZILBRYSQ?

ZILBRYSQ increases your chance of getting serious and life-threatening meningococcal infections. This can be an infection of the linings of the brain and spinal cord called meningitis. It can also be an infection of the blood called septicemia. This infection may quickly become life-threatening or fatal if not recognized and treated early.

Call your healthcare provider or seek emergency care right away if you have any signs or symptoms of meningococcal infection:

- Headache with any of these other symptoms:
 - nausea or vomiting
 - stiff neck
 - stiff back
 - fever
- Fever with or without rash
- Eyes sensitive to light
- Confusion
- Muscle aches with flu-like symptoms

Getting your Meningococcal Vaccines

- Complete or update two types of meningococcal vaccines (for both serogroup B and serogroup A, C, W, and Y infections) at least 2 weeks before your first dose of ZILBRYSQ if you have not already had these vaccines.
- Your doctor will review your vaccine history and let you know which vaccines you need.
- Vaccinations do not prevent all meningococcal infections. These infections may still occur. You will need to watch for signs and symptoms of meningococcal infection even after receiving the vaccines.

If your doctor decides that urgent treatment with ZILBRYSQ is needed and you have not completed or updated vaccinations for meningococcal infections at least 2 weeks before your first ZILBRYSQ dose:

- You should receive the meningococcal vaccinations as soon as possible.
- You must also receive a prescription for antibiotics from your doctor.
- Your healthcare provider will select an antibiotic for you to take.

ZILBRYSQ[®]

(zilucoplan) Injection


If you have already had both meningococcal vaccines in the past, discuss this with your doctor. You might need to get additional vaccines before you start ZILBRYSQ.

During treatment with ZILBRYSQ, you may also need additional doses of meningococcal vaccines. It is important to discuss this with your doctor to ensure that your vaccination status is always up to date throughout treatment with ZILBRYSQ.

Patient Safety Card

Your doctor will give you a **Patient Safety Card**.

- The card includes important information about your medical treatment.
- Keep this card with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ.



Show the **Patient Safety Card** to any healthcare provider you go to for treatment.

- The card lets them know about your ZILBRYSQ treatment.
- It will help them diagnose and treat possible meningococcal infection promptly.

Call your doctor or seek emergency care right away for any symptoms of meningococcal infection.

What is the ZILBRYSQ REMS?

A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the US Food and Drug Administration (FDA) can require for certain medicines to ensure they are used safely. When there is a REMS, drug companies and healthcare providers must take extra steps to make sure the benefits of using the drug are greater than the risks.

ZILBRYSQ has a REMS because it increases your chance of getting a meningococcal infection. This infection can quickly become life-threatening or fatal if not recognized and treated early.

How will I get ZILBRYSQ?

Only certain pharmacies can fill your ZILBRYSQ prescription. The pharmacies that are part of the ZILBRYSQ REMS will fill your prescription and ship it to you.

If you have questions about the ZILBRYSQ REMS, you can call the REMS or visit the REMS website.

Call: 1-877-414-8353 Monday through Friday, 9:00 AM – 5:00 PM Eastern Time

Visit: www.ZILBRYSQREMS.com

Potential cases of meningococcal infections should be reported immediately to UCB, Inc. at 1-844-599-2273

You are encouraged to report other adverse reactions of ZILBRYSQ to UCB Inc. or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.